MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Impairment of intangible assets
    • Stock-based compensation
    • Depreciation expense
Negative Cash Flow Breakdown
    • Trade and other payables
    • Prepaid expenses
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-15,790
-1,178
-2,314
-939
Depreciation expense
2
2
3
0
Loss on disposal
-
0
-
-
Stock-based compensation
105
182
108
206
Impairment of intangible assets
13,533
-
-
-
Change in fair value of derivative warrant liabilities
0
0
40
-1,427
Deferred income tax benefit
-
-1,700
0
0
Receivables
0
0
0
0
Prepaid expenses
174
-136
103
-84
Trade and other payables
-897
863
36
-1,067
Net cash used in operating activities
-3,221
-1,695
-2,230
-3,143
Maturity of short-term investments
-
0
0
-
Purchase of short-term investments
-
0
0
0
Net cash provided by investing activities
-
0
0
0
Proceeds from issuance of common stock from common warrant exercise
-
0
4,040
-
Gross proceeds from issuance of common stock and warrants from private placement
-
0
-
-
Payment of stock issuance costs
0
0
0
0
Net cash used in financing activities
0
0
4,040
0
Net decrease in cash and cash equivalents
-3,221
-1,695
1,810
-3,143
Cash and cash equivalents, beginning of period
16,977
16,862
16,862
22,133
Cash and cash equivalents, end of period
13,756
16,977
18,672
16,862
Cash
2,712
-
-
-
Cash equivalents
11,044
-
-
-
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Net decrease in cashand cash...-$3,221K (-51.36%↓ Y/Y)Impairment of intangibleassets$13,533K Stock-based compensation$105K (-65.23%↓ Y/Y)Depreciation expense$2K (0.00%↑ Y/Y)Net cash used inoperating activities-$3,221K (-78.85%↓ Y/Y)Canceled cashflow$13,640K Net loss-$15,790K (-369.66%↓ Y/Y)Trade and otherpayables-$897K (-226.16%↓ Y/Y)Prepaid expenses$174K (270.21%↑ Y/Y)

Grace Therapeutics, Inc. (GRCE)

Grace Therapeutics, Inc. (GRCE)